Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02344264

Enrollment

Registered

2015-01-22

Start date

2015-01-31

Completion date

2015-09-30

Last updated

2015-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Replacement, Hip, Pain, Postoperative, Ropivacaine, Therapeutic Use

Keywords

US guided nerve block, Total hip Arthroplasty, NCFL, nervus cutaneous femoralis lateralis

Brief summary

The patients will be included the 1. or 2. day after surgery. All THA patients will be screened. Those reporting VAS \> 40 during active 30 degrees hip flexion will be asked to participate. Included patients will receive 2xNCFL (singleshot) first placebo (8 ml saline) and then ropivacaine (8 ml ropivacaine 7,5mg/ml) or the other way around (randomized). There will be 45 minutes between the two blockades. The blockades will be ultrasound guided.

Interventions

DRUGRopivacaine

Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml). Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.

DRUGSaline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 85 Years

Healthy volunteers

Inclusion criteria

* THA within 48 hours and VAS\>40 during active 30 degrees hip flexion despite conventional pain medication. * informed consent * ASA 1-3 * BMI 18-40

Exclusion criteria

* Unable to communicate in danish * Allergic reactions toward drugs used * Abuse of alcohol/drugs * Unable to cooperate * Pregnant women

Design outcomes

Primary

Measure	Time frame
Difference in VAS between NCFL and placebo during active 30 degrees hip flexion	45 min

Secondary

Measure	Time frame
Difference in mean VAS between the groups during active hip flexion	15, 30, 45, 60, 75, 90 min
Difference in mean VAS between the groups at rest	15, 30, 45, 60, 75, 90 min

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026